Search

Your search keyword '"Paxlovid (Medication)"' showing total 55 results
Start Over Descriptor "Paxlovid (Medication)" Journal fair disclosure wire
55 results on '"Paxlovid (Medication)"'

1. Event Brief of Pfizer Inc at JPMorgan Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Albert Bourla - Pfizer Inc,Chairman of the Board, Chief Executive Officer CONFERENCE CALL PARTICIPANTS . Chris Schott - JPMorgan,Analyst OVERVIEW Company Summary FINANCIAL DATA 1. Undetermined Undetermined [...]

Published
2025

2. Pfizer Inc at JPMorgan Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation CHRIS SCHOTT, ANALYST, JPMORGAN: Thank you. Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside chat with Albert Bourla, Chairman and [...]

Published
2025

3. Event Brief of Pfizer Inc to Host Full-Year 2025 Guidance Call - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Executives -- Conferences, meetings and seminars, Financial markets -- Conferences, meetings and seminars, Financial statements -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Francesca DeMartino - Pfizer Inc,Senior Vice President, Chief Investor Relations Officer . Albert Bourla - Pfizer Inc,Chairman of the Board, Chief Executive Officer . David Denton - [...]

Published
2024

4. Pfizer Inc to Host FullYear 2025 Guidance Call - Final

Subjects
Pfizer Inc., Executives, Financial statements, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's analyst and investor call to review full-year 2025 financial guidance. Today's call is being recorded. At this time, I would like [...]

Published
2024

5. Event Brief of Pfizer Inc at UBS Global Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc,Executive Vice President, Chief US Commercial Officer CONFERENCE CALL PARTICIPANTS . Trung Huynh - UBS Equities,Analyst OVERVIEW Company Summary FINANCIAL DATA PRESENTATION Presentation [...]

Published
2024

6. Pfizer Inc at UBS Global Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation TRUNG HUYNH, ANALYST, UBS EQUITIES: Okay, great. I think we're at the half hour. So good afternoon, everyone. My name is Trung Huynh. I'm the large-cap pharma analyst here [...]

Published
2024

7. Event Brief of Q3 2024 Pfizer Inc Earnings Call - Final

Subjects
The Goldman Sachs Group Inc. -- Company sales and earnings -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars -- Company sales and earnings, Investment banks -- Conferences, meetings and seminars -- Company sales and earnings, Pharmaceutical industry -- Conferences, meetings and seminars -- Company sales and earnings, Company earnings/profit, Business, Abrysvo (Vaccine), Vyndaqel (Medication), Paxlovid (Medication), Oxbryta (Medication)
Abstract

CORPORATE PARTICIPANTS . Francesca DeMartino - Pfizer Inc,Chief Investor Relations Officer, Senior Vice President . Albert Bourla - Pfizer Inc,Chairman of the Board, Chief Executive Officer . Dave Denton - [...]

Published
2024

8. Q3 2024 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Abrysvo (Vaccine), Vyndaqel (Medication), Paxlovid (Medication), Oxbryta (Medication)
Abstract

Presentation OPERATOR: (Operator Instructions) Good day, everyone, and welcome to Pfizer's third-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the [...]

Published
2024

9. Event Brief of Pfizer Inc at Morgan Stanley Global Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Dave Denton - Pfizer Inc,EVP & CFO CONFERENCE CALL PARTICIPANTS . Terence Flynn - Morgan Stanley & Co. LLC,Analyst OVERVIEW Company Summary FINANCIAL DATA PRESENTATION Presentation 1. [...]

Published
2024

10. Event Brief of Q2 2024 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars -- Company sales and earnings, Cantor Fitzgerald L.P. -- Conferences, meetings and seminars -- Company sales and earnings, Chairpersons -- Conferences, meetings and seminars, Company earnings/profit, Business, Padcev (Medication), Abrysvo (Vaccine), Nurtec (Medication), Vyndaqel (Medication), Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Francesca DeMartino - Pfizer Inc,Chief Investor Relations Officer, Senior Vice President . Albert Bourla - Pfizer Inc,Chairman of the Board, Chief Executive Officer . David Denton - [...]

Published
2024

11. Q2 2024 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- Company sales and earnings, Company earnings/profit, Business, Padcev (Medication), Abrysvo (Vaccine), Nurtec (Medication), Vyndaqel (Medication), Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's second-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over [...]

Published
2024

12. Event Brief of Q1 2024 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Elrexfio (Medication), Padcev (Medication), Abrysvo (Vaccine), Nurtec (Medication), Vyndaqel (Medication), Ibrance (Medication), Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc.,Executive VP & Chief U.S. Commercial Officer . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Alexandre de Germay - [...]

Published
2024

13. Q1 2024 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Pfizer Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Elrexfio (Medication), Padcev (Medication), Abrysvo (Vaccine), Nurtec (Medication), Vyndaqel (Medication), Ibrance (Medication), Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's First Quarter 2024 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call [...]

Published
2024

14. Event Brief of Pfizer Inc To Acquire Seagen Inc - Final

Subjects
UBS Investment Bank -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Seagen Inc. -- Conferences, meetings and seminars, Citigroup Inc. -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Financial services industry -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Securities industry, Financial services industry, Business, Padcev (Medication), Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Chris Boshoff - Pfizer Inc.,Executive VP and Chief Oncology Research & Development Officer . David M. [...]

Published
2023

15. Pfizer Inc To Acquire Seagen Inc - Final

Subjects
Pfizer Inc. -- Forecasts and trends, Seagen Inc. -- Forecasts and trends, Biotechnology industry -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Padcev (Medication), Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone. And welcome to Pfizer's Analyst and Investor Call to review full year 2024 financial guidance. Today's call is being recorded. At this time, I would [...]

Published
2023

16. Q3 2023 GeoVax Labs Inc Earnings Call - Final

Subjects
Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good afternoon and welcome, everyone to the GeoVax Third Quarter 2023 corporate update call. My name is Mandy, and I will facilitate today's call. With me are David [...]

Published
2023

17. Q3 2023 Codexis Inc Earnings Call - Final

Subjects
Pfizer Inc. -- Company sales and earnings, Codexis Inc. -- Company sales and earnings, Biological products industry -- Company sales and earnings, Chief operating officers, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Welcome to Codexis third-quarter 2023 earnings conference call. (Operator Instructions) Please note, this event is being recorded. And now I'll turn the call over to Carrie McKim, Director [...]

Published
2023

18. Q3 2023 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc., Pharmaceutical industry, Business, Abrysvo (Vaccine), Nurtec (Medication), Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's Third Quarter 2023 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call [...]

Published
2023

19. Event Brief of Q3 2023 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Abrysvo (Vaccine), Nurtec (Medication), Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc.,Executive VP & Chief Business Innovation Officer . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Angela Hwang - Pfizer [...]

Published
2023

20. Event Brief of Pfizer Inc To Host Investment Analysts Call - Final

Subjects
UBS Investment Bank -- Conferences, meetings and seminars, The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Citigroup Inc. -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Financial services industry -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Securities industry, Financial services industry, Business, Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . David M. Denton - Pfizer Inc.,CFO & Executive VP . Francesca DeMartino - Pfizer Inc.,Chief Investor [...]

Published
2023

21. Pfizer Inc To Host Investment Analysts Call - Final

Subjects
Pfizer Inc. -- Forecasts and trends, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to review amended U.S. government PAXLOVID Supply Agreement and updated full year 2023 guidance. Today's call is [...]

Published
2023

22. Pfizer Inc at JPMorgan U.S. All Stars Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars -- Forecasts and trends, Chief financial officers -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Forecasts and trends, Market trend/market analysis, Business, Paxlovid (Medication)
Abstract

Presentation CHRISTOPHER THOMAS SCHOTT, SENIOR ANALYST, JPMORGAN CHASE & CO, RESEARCH DIVISION: We're ready to go. So good morning, everybody. I'm Chris Schott, the pharma analyst here at JPMorgan, and [...]

Published
2023

23. Event Brief of Q1 2023 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Xtandi (Medication), Nurtec (Medication), Adcetris (Medication), Prevnar 20 (Vaccine), Paxlovid (Medication), Talzenna (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc.,Executive VP & Chief Business Innovation Officer . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Angela Hwang - Pfizer [...]

Published
2023

24. Q1 2023 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Pfizer Inc., Pharmaceutical industry, Business, Xtandi (Medication), Nurtec (Medication), Adcetris (Medication), Prevnar 20 (Vaccine), Paxlovid (Medication), Talzenna (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's First Quarter 2023 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call [...]

Published
2023

25. Q4 2022 Atea Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results and Business Update Conference Call. (Operator Instructions) Please be advised [...]

Published
2023

26. Event Brief of Q4 2022 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- International economic relations -- Conferences, meetings and seminars -- Company sales and earnings, Citigroup Inc. -- Company sales and earnings -- Conferences, meetings and seminars -- International economic relations, Financial services industry -- Company sales and earnings -- Conferences, meetings and seminars -- International economic relations, Pharmaceutical industry -- Conferences, meetings and seminars -- International economic relations -- Company sales and earnings, Financial services industry, Company earnings/profit, Business, Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc.,Executive VP & Chief Business Innovation Officer . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Angela Hwang - Pfizer [...]

Published
2023

27. Q4 2022 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- International economic relations -- Company sales and earnings, Pharmaceutical industry -- International economic relations -- Company sales and earnings, Company earnings/profit, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's Fourth Quarter 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call [...]

Published
2023

28. Pfizer Inc at JPMorgan Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation CHRISTOPHER THOMAS SCHOTT, SENIOR ANALYST, JPMORGAN CHASE & CO, RESEARCH DIVISION: Good afternoon. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat today [...]

Published
2023

29. Pfizer Inc at Evercore ISI HealthCONx Conference (Virtual) - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars -- Forecasts and trends, Financial analysts -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Forecasts and trends, Market trend/market analysis, Business, Prevnar 20 (Vaccine), Paxlovid (Medication)
Abstract

Presentation UMER RAFFAT, SENIOR MD & SENIOR ANALYST OF EQUITY RESEARCH, EVERCORE ISI INSTITUTIONAL EQUITIES, RESEARCH DIVISION: Okay. Well, my last session, my last fireside for our 2022 Healthcare Conference. [...]

Published
2022

30. Pardes Biosciences Inc at Jefferies London Healthcare Conference - Final

Subjects
Jefferies Financial Group Inc. -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation DENNIS DING, ANALYST, JEFFERIES FINANCIAL GROUP INC.: Hi. Good morning, everybody. My name is Dennis Ding, biotech analyst here at Jefferies. Welcome to the 2022 London Healthcare Conference. I'm [...]

Published
2022

31. Q3 2022 Codexis Inc Earnings Call - Final

Subjects
Codexis Inc. -- Company sales and earnings, Biological products industry -- Company sales and earnings, Chief operating officers, Company earnings/profit, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Welcome to the Codexis Third Quarter 2022 Earnings Conference Call. (Operator Instructions) At this time, I will now turn the conference over to Brendan Strong from Argot Partners. [...]

Published
2022

32. Event Brief of Q3 2022 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars -- Company sales and earnings, Citigroup Inc. -- Company sales and earnings -- Conferences, meetings and seminars, Financial services industry -- Company sales and earnings -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Company sales and earnings, Financial services industry, Company earnings/profit, Business, Xtandi (Medication), Nurtec (Medication), Prevnar 20 (Vaccine), Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc.,Executive VP & Chief Business Innovation Officer . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Angela Hwang - Pfizer [...]

Published
2022

33. Q3 2022 Pfizer Inc Earnings Call - Final

Subjects
Pfizer Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Xtandi (Medication), Nurtec (Medication), Prevnar 20 (Vaccine), Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's Third Quarter 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call [...]

Published
2022

34. Todos Medical Ltd at Emerging Growth Conference - Final

Subjects
Conferences and conventions -- Conferences, meetings and seminars, Company growth, Business, Paxlovid (Medication)
Abstract

Presentation ANA BERRY, ANALYST, EMERGING GROWTH CONFERENCE: Welcome back, everyone. Next up, we have Todos Medical Ltd. It trades on the OTCQB under the symbol TOMDF, an engineer's life-saving diagnostic [...]

Published
2022

35. Q3 2022 Enanta Pharmaceuticals Inc Earnings Call - Final

Subjects
Enanta Pharmaceuticals Inc., Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good afternoon, and welcome to Enanta Pharmaceuticals' Fiscal Third Quarter 2022 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded. I would [...]

Published
2022

36. Q2 2022 Atea Pharmaceuticals Inc Earnings Call - Final

Subjects
Company business planning, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. (Operator Instructions) Please note that today's conference is being recorded. I [...]

Published
2022

37. Q2 2022 Codexis Inc Earnings Call - Final

Subjects
Merck & Company Inc. -- Company sales and earnings, Pfizer Inc. -- Company sales and earnings, Codexis Inc. -- Company sales and earnings, Biological products industry -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Welcome to the Codexis Second Quarter 2022 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded. And now I'll turn the call over to Brendan [...]

Published
2022

38. Event Brief of Q2 2022 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars -- Company sales and earnings, Citigroup Inc. -- Company sales and earnings -- Conferences, meetings and seminars, Company earnings/profit, Business, Ibrance (Medication), Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc.,Executive VP & Chief Business Innovation Officer . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Angela Hwang - Pfizer [...]

Published
2022

39. Q2 2022 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Pfizer Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Ibrance (Medication), Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's Second Quarter 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call [...]

Published
2022

40. Pfizer Inc at Goldman Sachs Global Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation CHRIS SHIBUTANI, RESEARCH ANALYST, GOLDMAN SACHS GROUP, INC., RESEARCH DIVISION: Welcome to our session here at the Goldman Sachs Healthcare Conference. I'll have to let Keira know that we [...]

Published
2022

41. Codexis Inc at Jefferies Healthcare Conference - Final

Subjects
Codexis Inc. -- Conferences, meetings and seminars, Biological products industry -- Conferences, meetings and seminars, Financial statements -- Conferences, meetings and seminars, Enzymes -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation MATTHEW STANTON: Alright. Welcome, everyone, to the Jefferies Global Healthcare Conference. I'm Matt Stanton. I'm on the Life Science Tools and diagnostics team here at Jefferies. It's my pleasure [...]

Published
2022

42. Pfizer Inc to Discuss Expanding Access & Affordability: A Fireside Chat with Pfizer Call - Final

Subjects
Pfizer Inc., World health -- Social aspects, Business plans -- Social aspects, Business planning -- Social aspects, Business, Paxlovid (Medication)
Abstract

Presentation CAROLINE ROAN, CHIEF SUSTAINABILITY OFFICER & SVP, GLOBAL HEALTH & SOCIAL IMPACT, PFIZER INC.: Hello, and thank you for joining us today. I'm Caroline Roan, Pfizer's Chief Sustainability Officer [...]

Published
2022

43. Pfizer Inc at Sanford C Bernstein Strategic Decisions Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation AARON GAL, SENIOR RESEARCH ANALYST, SANFORD C. BERNSTEIN & CO., LLC., RESEARCH DIVISION: Okay, guys. Let us go ahead and start. Thank you for being here today. And obviously, [...]

Published
2022

44. Codexis Inc at UBS Global Life Science Conference (Virtual) - Final

Subjects
Merck & Company Inc. -- Conferences, meetings and seminars, UBS Investment Bank -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Codexis Inc. -- Conferences, meetings and seminars, Biological products industry -- Conferences, meetings and seminars, Insurance industry -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Securities industry, Insurance industry, Business, Januvia (Medication), Paxlovid (Medication)
Abstract

Presentation JOHN NEWTON SOURBEER, EQUITY RESEARCH ASSOCIATE, UBS INVESTMENT BANK, RESEARCH DIVISION: Hi. I'm John Sourbeer, UBS' life science tools and pharma services analyst. Welcome to the last panel of [...]

Published
2022

45. Q1 2022 Codexis Inc Earnings Call - Final

Subjects
Pfizer Inc., Codexis Inc., Biological products industry, Pharmaceutical industry, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Welcome to the Codexis First Quarter 2022 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded. And now I'll turn the call over to Brendan [...]

Published
2022

46. Event Brief of Q1 2022 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars -- Company sales and earnings, Pharmaceutical industry -- Conferences, meetings and seminars -- Company sales and earnings, Company earnings/profit, Business, Xeljanz (Medication), Ibrance (Medication), Lorbrena (Medication), Paxlovid (Medication)
Abstract

CORPORATE PARTICIPANTS . Aamir Malik - Pfizer Inc.,Executive VP & Chief Business Innovation Officer . Albert Bourla - Pfizer Inc.,Chairman of the Board & CEO . Angela Hwang - Pfizer [...]

Published
2022

47. Q1 2022 Pfizer Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Pfizer Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Xeljanz (Medication), Ibrance (Medication), Lorbrena (Medication), Paxlovid (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to Pfizer's First Quarter 2022 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call [...]

Published
2022

48. Pfizer Inc at Truist Financial AI Symposium Biotech & Tools - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Financial analysts -- Conferences, meetings and seminars, Biotechnology -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Business, Paxlovid (Medication)
Abstract

Presentation ROBYN KAY SHELTON KARNAUSKAS, RESEARCH ANALYST, TRUIST SECURITIES, INC., RESEARCH DIVISION: Hello, and good morning or good afternoon, everyone. My name is Robyn Karnauskas, one of the biotech analysts [...]

Published
2022

49. Q4 2021 Codexis Inc Earnings Call - Final

Subjects
Merck & Company Inc. -- Company sales and earnings, Pfizer Inc. -- Company sales and earnings, Codexis Inc. -- Company sales and earnings, Biological products industry -- Company sales and earnings, Financial statements, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Business, Paxlovid (Medication)
Abstract

Presentation OPERATOR: Greetings, and welcome to the Codexis Fourth Quarter and Full Year 2021 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now [...]

Published
2022

50. Pfizer Inc at SVB Leerink Global Healthcare (Virtual) - Final

Subjects
Pfizer Inc., Vaccines, Business, Paxlovid (Medication)
Abstract

Presentation DAVID REED RISINGER, SENIOR MD, SVB LEERINK HOLDINGS LLC: Great. Good afternoon, everyone, and thank you so much for joining us for a discussion with Pfizer's hospital leadership team. [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results